[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Mikami Y, Nakajima M, Hashimoto H, Irei I, Matsushima T, Kawabata S, Manabe T: Primary pulmonary primitive neuroectodermal tumor (PNET). A case report. Pathol Res Pract; 2001;197(2):113-119; discussion 121-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary primitive neuroectodermal tumor (PNET). A case report.
  • We describe a rare case of a primary primitive neuroectodermal tumor (PNET) in the lung of a 17-year-old girl.
  • Immunohistochemically, the tumor was positive for the MIC2 gene product, whereas AE1/AE3, CAM5.2, and a variety of neuroendocrine markers such as chromogranin A, synaptophysin, and ProGRP, were negative.
  • Three months after the lobectomy, recurrent tumors were noted in the mediastinum and right thoracic wall, and she died despite combined chemotherapy and radiation therapy.
  • This case indicates that the primary pulmonary PNET is a highly aggressive neoplasm occurring at a young age, and should prompt combined systemic chemotherapy, even though it is organ-confined.
  • [MeSH-major] Lung Neoplasms / pathology. Neuroectodermal Tumors, Primitive, Peripheral / pathology
  • [MeSH-minor] Adolescent. Carcinoma, Small Cell / diagnosis. Combined Modality Therapy. DNA Primers / chemistry. DNA, Neoplasm / analysis. Diagnosis, Differential. Fatal Outcome. Female. Humans. Karyotyping. Oncogene Proteins, Fusion / genetics. Proto-Oncogene Protein c-fli-1. RNA-Binding Protein EWS. Radiography, Thoracic. Reverse Transcriptase Polymerase Chain Reaction. Tomography, X-Ray Computed. Transcription Factors / genetics. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11261815.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / EWS-FLI fusion protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Protein c-fli-1; 0 / RNA-Binding Protein EWS; 0 / Transcription Factors
  •  go-up   go-down


2. Hage R, Seldenrijk K, de Bruin P, van Swieten H, van den Bosch J: Pulmonary large-cell neuroendocrine carcinoma (LCNEC). Eur J Cardiothorac Surg; 2003 Apr;23(4):457-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary large-cell neuroendocrine carcinoma (LCNEC).
  • OBJECTIVE: The experiences on the treatment of seven consecutive patients with large-cell neuroendocrine carcinoma (LCNEC) were studied, observed over 6 years from 1992.
  • Together with the carcinoids (atypical and typical) and the small-cell lung carcinoma (SCLC), it forms the spectrum of neuroendocrine tumors.
  • Three patients received adjuvant chemotherapy and one, adjuvant radiotherapy.
  • CONCLUSIONS: LCNEC is a high-grade neuroendocrine tumor with a poor prognosis.
  • In our patients, after surgical resection or multimodality treatment, all have developed widespread metastatic disease with a rapidly fatal course.
  • Due to the rarity of this tumor, the incidence, prognosis and optimal treatment remain to be determined.
  • [MeSH-major] Carcinoma, Large Cell / surgery. Carcinoma, Neuroendocrine / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for pulmonary large cell neuroendocrine carcinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2003 Oct;24(4):671-2; author reply 672-3 [14500107.001]
  • (PMID = 12694759.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 13
  •  go-up   go-down


3. Nagasaki T, Tsuchiya T, Tagawa T, Honda S, Yamasaki N, Miyazaki T, Hidaka S, Hayashi T, Nagayasu T: Analysis of 5-fluorouracil-related enzymes in pulmonary neuroendocrine carcinoma: differences in biological properties compared to epithelial carcinoma. Clin Lung Cancer; 2010 Nov 1;11(6):412-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of 5-fluorouracil-related enzymes in pulmonary neuroendocrine carcinoma: differences in biological properties compared to epithelial carcinoma.
  • Few data are available on these enzymes in pulmonary neuroendocrine carcinoma, because 5-FU appears to have minimal effect on such carcinomas.
  • PATIENTS AND METHODS: This study investigated 5-FU-related enzymes in large-cell neuroendocrine carcinoma (LCNEC; n = 31) and small-cell lung carcinoma (SCLC; n = 15), comparing expression levels with epithelial carcinomas including adenocarcinoma (ADC; n = 34) and squamous cell carcinoma (SCC; n = 13) obtained from 93 patients with primary lung tumors.
  • When we divide the data by pathology into epithelial carcinoma and neuroendocrine carcinoma, malignant potentials and prognoses correlated with mRNA levels in epithelial carcinoma, but not in neuroendocrine carcinoma.
  • Immunohistochemically, neuroendocrine carcinomas were immunonegative for DPD.
  • CONCLUSION: Neuroendocrine carcinomas show characteristic patterns of expression for 5-FU-related enzymes, including low DPD mRNA and protein level and high TS mRNA level compared with adenocarcinomas.
  • These results partially explain why 5-FU-based chemotherapy shows minimal efficacy against SCLC.
  • Conversely, clinicopathological data and survival analysis indicates that 5-FU-related enzymes themselves might not affect the malignant potential of neuroendocrine carcinoma.
  • Expressional differences in 5-FU-related enzymes among pathologies may provide valuable information for tailor-made chemotherapy.
  • [MeSH-major] Dihydrouracil Dehydrogenase (NADP) / genetics. Lung Neoplasms / enzymology. Orotate Phosphoribosyltransferase / genetics. Thymidylate Synthase / genetics
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / enzymology. Aged. Antimetabolites, Antineoplastic / pharmacology. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / enzymology. Carcinoma, Neuroendocrine / drug therapy. Carcinoma, Neuroendocrine / enzymology. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / enzymology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / enzymology. Drug Resistance, Neoplasm. Female. Fluorouracil / pharmacology. Gene Expression Regulation, Neoplastic. Humans. Male. RNA, Messenger / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21062732.001).
  • [ISSN] 1938-0690
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / RNA, Messenger; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.1.1.45 / Thymidylate Synthase; EC 2.4.2.10 / Orotate Phosphoribosyltransferase; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Yamasaki T, Shimazaki H, Aida S, Tamai S, Tamaki K, Hiraide H, Mochizuki H, Matsubara O: Primary small cell (oat cell) carcinoma of the breast: report of a case and review of the literature. Pathol Int; 2000 Nov;50(11):914-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was alive and well without disease 16 months after modified radical mastectomy and subsequent chemotherapy.
  • The tumor cells revealed morphologic similarity to oat cell carcinoma of the lung and immunohistochemical expression of neuroendocrine markers.
  • Review of nine previously reported cases and this case of primary small cell carcinoma of the breast has revealed that this type of tumor shows prominent vascular invasion, frequent lymph node metastasis, infrequent expression of estrogen receptor, and also very poor prognosis.
  • Immunohistochemical study for the c-kit proto-oncogene product, which has been reported to be a specific marker for pulmonary small cell carcinoma, demonstrated positive reactivity in approximately 80% of the tumor cells of this case, which is the first report according to our knowledge.
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biopsy, Needle. Chemotherapy, Adjuvant. Cytoplasmic Granules / ultrastructure. Female. Humans. Immunohistochemistry. Mastectomy, Modified Radical. Neoplasm Proteins / analysis. Neurosecretory Systems / ultrastructure

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11107070.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] AUSTRALIA
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Number-of-references] 21
  •  go-up   go-down


5. Moore AM, Einhorn LH, Estes D, Govindan R, Axelson J, Vinson J, Breen TE, Yu M, Hanna NH: Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer; 2006 Apr;52(1):93-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Gefitinib has demonstrated activity in patients with non-small cell lung cancer (NSCLC).
  • Although, EGFR is not over-expressed in small cell lung cancer (SCLC), we postulated that gefitinib might affect tumor growth through other mechanisms.
  • Eligibility criteria included pathologic proof of a neuroendocrine tumor, especially small cell cancer, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2, prior treatment with one or two prior chemotherapy regimens and adequate end-organ function.
  • Small cell lung cancer accounted for 18 of the 19 patients and one patient had metastatic Merkel cell carcinoma.
  • Twelve patients (63%) had chemo-sensitive disease, defined as progression greater than three months from completion of prior chemotherapy; 7 (37%) had chemo-refractory disease; 13 (68%) had one prior chemotherapy regimen.
  • Grade 3 toxicities included: fatigue in three patients (15.8%), pulmonary toxicities in three (15.8%) and one patient (5.3%) each with hyperglycemia or pain.
  • Median time to progression (TTP) was 50 days (95% CI = 21-58 days).
  • CONCLUSION: Although gefitinib has activity in select patients with NSCLC, this study failed to demonstrate benefit in patients with small cell lung cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Small Cell / drug therapy. Drug Resistance, Neoplasm. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Aged. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Recurrence, Local. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lung Cancer. 2006 Aug;53(2):255 [16762444.001]
  • (PMID = 16488055.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


6. Igawa S, Watanabe R, Ito I, Murakami H, Takahashi T, Nakamura Y, Tsuya A, Kaira K, Naito T, Endo M, Yamamoto N, Kameya T: Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer. Lung Cancer; 2010 Jun;68(3):438-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer.
  • BACKGROUND: Pulmonary large cell neuroendocrine carcinoma (LCNEC) shares several features with small cell lung carcinoma (SCLC).
  • While the diagnosis of LCNEC by biopsy specimens is challenging, a definitive diagnosis of this highly malignant tumor is critical in unresectable cases to determine the optimal therapeutic strategy.
  • The objective of this study was to assess the efficacy of chemotherapy for unresectable high-grade non-small cell neuroendocrine carcinoma (HNSCNEC) called by us, which likely includes most LCNECs except for combined types, and to compare the efficacy of chemotherapy for HNSCNEC, with that for extended disease SCLC (ED-SCLC).
  • We simultaneously evaluated the clinical response to the chemotherapy and survival time of the 14 HNSCNEC and 77 ED-SCLC patients.
  • RESULTS: The chemotherapy regimens in the 14 patients with unresectable HNSCNEC were platinum-based combination regimens or irinotecan or vinorelbine or docetaxel alone.
  • The chemotherapy regimens in the 77 patients with ED-SCLC were platinum-based combination regimens.
  • We assessed an objective response rate, a one-year survival rate, and median survival time as 50% (7/14), 34% and 10 months, respectively, in the 14 HNSCNEC patients, and as 53% (41/77), 48% and 12.3 months, respectively, in the 77 ED-SCLC patients.
  • CONCLUSION: The clinical efficacy of chemotherapy for unresectable HNSCNECs, including most LCNECs, is comparable to that for ED-SCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neuroendocrine Tumors / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Disease Progression. Drug Therapy, Combination. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Platinum Compounds / administration & dosage. Platinum Compounds / adverse effects. Survival Analysis. Taxoids / administration & dosage. Taxoids / adverse effects. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19699548.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Platinum Compounds; 0 / Taxoids; 15H5577CQD / docetaxel; 5V9KLZ54CY / Vinblastine; 7673326042 / irinotecan; Q6C979R91Y / vinorelbine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Erelel M, Toker SA, Yakar F, Yakar AA, Yildiz R, Kaya ZB: Multifocal endobronchial carcinoid tumors: a rare case. J Bronchology Interv Pulmonol; 2010 Apr;17(2):158-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography of the chest showed tubular densities in the bilateral lower lobes and a 15-mm soft-tissue mass in the right lower lobe without any enlargement in the mediastinal lymph nodes.
  • On positron emission tomography scan, there was no fluorodeoxyglucose uptake in any of these lesions.
  • The pathologic examination of biopsies showed neuroendocrine neoplasm and typical bronchial carcinoid tumor.
  • Although the only effective treatment for a bronchial carcinoid is complete surgical excision of the tumor, surgical resection was not performed in our patient because of multiple, bilateral, biopsy-proven endobronchial tumors.
  • Radiation and chemotherapy are generally reserved for symptomatic and metastatic disease, which was the treatment of choice for our patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23168735.001).
  • [ISSN] 1944-6586
  • [Journal-full-title] Journal of bronchology & interventional pulmonology
  • [ISO-abbreviation] J Bronchology Interv Pulmonol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Kozuki T, Fujimoto N, Ueoka H, Kiura K, Fujiwara K, Shiomi K, Mizobuchi K, Tabata M, Hamazaki S, Tanimoto M: Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma. J Cancer Res Clin Oncol; 2005 Mar;131(3):147-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma.
  • PURPOSE: According to the World Health Organization (WHO) classification of pulmonary large cell neuroendocrine carcinoma (LCNEC), one of the neuroendocrine tumors of the lung, is considered as a variant of non-small cell lung carcinoma.
  • The objective of this study was to investigate the treatment strategy for LCNEC.
  • Of five patients with stage IV disease, three received platinum-based chemotherapy but no patient achieved PR.
  • Of five patients with gefitinib as salvage therapy, one achieved PR.
  • To improve the outcome, we must evaluate the effectiveness of adjuvant or neoadjuvant therapy in patients with resectable disease.
  • In addition, the evaluation of systemic and multimodality treatment strategies similar as in small cell lung cancer is worthy of consideration.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / therapy. Lung Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Neuroendocrine Tumors / therapy
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Quinazolines / administration & dosage. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 1995 Jul;86(7):698-705 [7559089.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1056-61 [9506349.001]
  • [Cites] Ann Thorac Surg. 2004 Apr;77(4):1168-72 [15063228.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):1992-2000 [11391577.001]
  • [Cites] Crit Rev Oncol Hematol. 2001 Jan;37(1):47-51 [11164718.001]
  • [Cites] Br J Cancer. 1996 May;73(10):1227-32 [8630283.001]
  • [Cites] Eur J Cardiothorac Surg. 2003 Apr;23(4):457-60 [12694759.001]
  • [Cites] Ann Thorac Surg. 2004 Apr;77(4):1163-7 [15063227.001]
  • [Cites] Lung Cancer. 2000 Sep;29(3):217-25 [10996424.001]
  • [Cites] Ann Thorac Surg. 2003 Feb;75(2):348-52 [12607637.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1108-12 [11571722.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Aug;124(2):285-92 [12167788.001]
  • [Cites] Ann Thorac Surg. 1997 Jan;63(1):180-5 [8993262.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):85-91 [11784874.001]
  • [Cites] Lung Cancer. 2003 May;40(2):173-80 [12711118.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):526-37 [9591721.001]
  • [Cites] Thorax. 1984 Mar;39(3):175-8 [6324409.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116 Suppl:S65-96 [11993704.001]
  • [Cites] Lung Cancer. 2002 Sep;37(3):287-92 [12234698.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):529-53 [1709558.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5880-7 [14676110.001]
  • [Cites] Br J Cancer. 2001 Jul 6;85(1):9-13 [11437395.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2136-40 [8174119.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):351-60 [14736927.001]
  • (PMID = 15538626.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Quinazolines; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; S65743JHBS / gefitinib
  •  go-up   go-down


9. Rossi G, Cavazza A, Marchioni A, Migaldi M, Bavieri M, Facciolongo N, Petruzzelli S, Longo L, Tamberi S, Crinò L: Kit expression in small cell carcinomas of the lung: effects of chemotherapy. Mod Pathol; 2003 Oct;16(10):1041-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kit expression in small cell carcinomas of the lung: effects of chemotherapy.
  • A significant number of small cell lung carcinomas shows overexpression of the proto-oncogene c-kit product, a tyrosine kinase known as Kit or CD117.
  • This molecular pathway seems somewhat implicated in promoting the neoplastic growth of small cell lung carcinoma.
  • The current pharmacological availability of its selective inhibitor, together with the promising clinical results in the management of CD117-positive neoplasms such as advanced gastrointestinal stromal tumors, aroused great interest among oncologists in also adopting this therapeutic strategy in other CD117-positive tumors.
  • We evaluated a series of 27 small cell lung carcinomas, comparing the expression of CD117 of the primary naïve tumor (before first-line chemotherapy) with the expression of the same neoplasm after postchemotherapy relapse.
  • No originally CD117-negative small cell carcinomas displayed immunoreactivity after chemotherapy.
  • CD117 expression was not statistically correlated with overall survival, occurrence of chemoresistance, or clinical response to chemotherapy.
  • We also evaluated CD117 expression in a series of 46 surgically resected non-small cell lung carcinomas (8 squamous cell carcinomas, 10 adenocarcinomas, 5 pleomorphic carcinomas, 10 typical and 3 atypical carcinoids, and 10 large cell neuroendocrine carcinomas).
  • Apart from small cell carcinomas, CD117 overexpression was observed in 6 of 10 large cell neuroendocrine carcinomas, whereas all the other histotypes resulted unstained.
  • We speculate that loss of CD117 expression after chemotherapy in a high proportion of SCLC indicates that in this tumor, Kit unlikely represents the product of a constitutive mutation, as instead shown in gastrointestinal stromal tumors.
  • Keeping this finding in mind, oncologists could re-test CD117 expression in relapsing small cell lung carcinomas in order to establish the best candidates for enrollment in ongoing clinical trials with Kit inhibitors.
  • Practically speaking, CD117 may be helpful in discriminating between pulmonary high-grade neuroendocrine tumors and other histotypes, but pathologists should be aware that treated small cell lung carcinomas may remain unstained in a not insignificant number of cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / metabolism. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Proto-Oncogene Proteins c-kit / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14559988.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Massoni Neto LM, Bianchi CP, Ab'Saber AM, Parra ER, Takagaki T, Pereira JC, Soares FA, Leite K, Capelozzi VL: p53 immunostaining is correlated with reduced survival and is not correlated with gene mutations in resected pulmonary large cell carcinomas. Braz J Med Biol Res; 2007 Aug;40(8):1045-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 immunostaining is correlated with reduced survival and is not correlated with gene mutations in resected pulmonary large cell carcinomas.
  • Malignancy of pulmonary large cell carcinomas (LCC) increases from classic LCC through LCC with neuroendocrine morphology (LCCNM) to large cell neuroendocrine carcinomas (LCNEC).
  • Because the malignancy of LCC is highly dependent on proteins with functions in the cell cycle, DNA repair, and apoptosis, p53 has been targeted as a potentially useful biological marker. p53 mutations in lung cancers have been shown to result in expression and protein expression also occurs in the absence of mutations.
  • To validate the importance of both p53 protein expression (by immunostaining) and p53 gene mutations in lung LCC (by PCR-single strand conformational polymorphism analysis of exons 5, 6, 7, and 8) and to study their relationships with clinical factors and sub-classification we investigated the correlation of p53 abnormalities in 15 patients with LCC (5 classic LCC, 5 LCNEC, and 5 LCCNM) who had undergone resection with curative intent.
  • After adjustment for stage, age, gender, chemotherapy, radiotherapy, and histological subtypes by multivariate analysis, p53 expression had an independent impact on survival.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17665040.001).
  • [ISSN] 0100-879X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


11. Doddoli C, Rollet G, Thomas P, Ghez O, Serée Y, Giudicelli R, Fuentes P: Is lung cancer surgery justified in patients with direct mediastinal invasion? Eur J Cardiothorac Surg; 2001 Aug;20(2):339-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is lung cancer surgery justified in patients with direct mediastinal invasion?
  • OBJECTIVE: To assess the results of the surgical treatment of patients with stage IIIB non-small cell lung carcinoma (NSCLC) invading the mediastinum (T4).
  • Three patients received a preoperative chemotherapy (n = 2) or radiochemotherapy (n = 1).
  • The lung resection consisted of a pneumonectomy in 25 patients and a lobectomy in four.
  • The procedure was extended to one of the following structures: superior vena cava (SVC) (n = 17), aorta (n = 1), left atrium (n = 5) and carina (n = 6).
  • Seventeen patients had a postoperative regimen including radiochemotherapy (n = 12), radiotherapy (n = 4), or chemotherapy (n = 1).
  • At completion of the study, 22 patients have died, two postoperatively and 10 from pulmonary causes without evidence of cancer.
  • CONCLUSIONS: Surgical management of T4 NSC lung cancer invading the mediastinum should be considered, in the absence of N2 disease, when a complete resection is achievable.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Mediastinum / pathology. Pneumonectomy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenocarcinoma / therapy. Adult. Aged. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / surgery. Carcinoma, Large Cell / therapy. Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / surgery. Carcinoma, Neuroendocrine / therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / therapy. Cause of Death. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11463554.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Foroulis CN, Iliadis KH, Mauroudis PM, Kosmidis PA: Basaloid carcinoma, a rare primary lung neoplasm: report of a case and review of the literature. Lung Cancer; 2002 Mar;35(3):335-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid carcinoma, a rare primary lung neoplasm: report of a case and review of the literature.
  • Basaloid carcinoma of the lung is a rare primary neoplasm, first described in 1992.
  • Basaloid carcinoma is an aggressive subtype of Non small cell lung cancer, with poor 5-year survival, even in stage I and II resected tumors.
  • Differential diagnosis from small cell, Neuroendocrine large cell and poorly differentiated squamous cell carcinoma is difficult to be made.
  • We report a patient with lung basaloid carcinoma, initially diagnosed and treated as small cell carcinoma.
  • Thoracotomy and resection of the tumor following chemotherapy, established the correct diagnosis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Lung Neoplasms
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Neoplasm Invasiveness. Pulmonary Disease, Chronic Obstructive / complications

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11844610.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 9
  •  go-up   go-down


13. Papotti M, Cassoni P, Sapino A, Passarino G, Krueger JE, Albores-Saavedra J: Large cell neuroendocrine carcinoma of the gallbladder: report of two cases. Am J Surg Pathol; 2000 Oct;24(10):1424-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell neuroendocrine carcinoma of the gallbladder: report of two cases.
  • We report two cases of primary large cell neuroendocrine carcinoma (LCNEC) of the gallbladder, which, to the best of our knowledge, represent the first description of this entity.
  • One of the tumors consisted entirely of LCNEC, whereas the second tumor was composed of LCNEC and the more common intestinal-type adenocarcinoma.
  • Both tumors were morphologically similar to their pulmonary counterpart and were characterized by large cells with prominent nucleoli, coarse chromatin, and a high mitotic rate.
  • Panendocrine markers were expressed in a variable proportion of tumor cells in both cases, and one of the cases also showed focal positivity for type 2 somatostatin receptors.
  • One of the tumors followed a rapidly fatal course despite aggressive surgical treatment and chemotherapy administration, and the second patient is still alive and disease-free 12 months after surgery.
  • From an academic standpoint, we now know that all the neuroendocrine tumors described in other organs can arise de novo in the gallbladder.
  • More importantly, however, the recognition of this rare tumor type carries important clinical implications in regard to the use of chemotherapeutic agents and supplemental treatments (for example, somatostatin analogs).
  • [MeSH-major] Carcinoma, Large Cell / secondary. Carcinoma, Neuroendocrine / secondary. Gallbladder Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Cholelithiasis / etiology. Cholelithiasis / pathology. Cholelithiasis / surgery. Chromogranin A. Chromogranins / analysis. Fatal Outcome. Humans. Immunoenzyme Techniques. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Male. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Synaptophysin / analysis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11023106.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Chromogranins; 0 / Neoplasm Proteins; 0 / Synaptophysin
  •  go-up   go-down


14. Gilbert JA, Frederick LM, Ames MM: The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res; 2000 Nov;6(11):4365-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells.
  • The carcinoid tumor is an uncommon neuroendocrine neoplasm the hallmark of which is excessive serotonin production.
  • Here, we report Western and Northern analyses detecting large quantities of AAAD polypeptide and mRNA in human carcinoid primary as well as metastatic tumors compared with normal surrounding tissues.
  • To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.
  • On exposure to other human tumor lines, carbidopa was lethal only to NCI-H146 and NCI-H209 small cell lung carcinoma (SCLC) lines (IC50 = 12 +/- 1 microM and 22 +/- 5 microM, respectively).
  • Carbidopa (100 microM) decreased growth of (but did not kill) SK-N-SH neuroblastoma and A204 rhabdomyosarcoma cells and did not affect proliferation of DU 145 prostate, MCF7 breast, or NCI-H460 large cell lung carcinoma lines.
  • For lung tumor lines (carcinoid, two SCLC, and one large cell lung carcinoma), AAAD activity was correlated with the potency of carbidopa-induced cytotoxicity.
  • [MeSH-major] Aromatic Amino Acid Decarboxylase Inhibitors. Carbidopa / pharmacology. Carcinoid Tumor / drug therapy. Carcinoma, Small Cell / drug therapy. Enzyme Inhibitors / pharmacology. Lung Neoplasms / drug therapy
  • [MeSH-minor] Cell Division / drug effects. Humans. Ileum / enzymology. Liver / enzymology. Microscopy, Electron. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11106255.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 58450
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Aromatic Amino Acid Decarboxylase Inhibitors; 0 / Enzyme Inhibitors; MNX7R8C5VO / Carbidopa
  •  go-up   go-down


15. Bing Z, Adegboyega PA: Metastasis of small cell carcinoma of lung into an ovarian mucinous neoplasm: immunohistochemistry as a useful ancillary technique for diagnosis and classification of rare tumors. Appl Immunohistochem Mol Morphol; 2005 Mar;13(1):104-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of small cell carcinoma of lung into an ovarian mucinous neoplasm: immunohistochemistry as a useful ancillary technique for diagnosis and classification of rare tumors.
  • The authors report the first case of ovarian mucinous adenocarcinoma with metastasis from a synchronous small cell neuroendocrine carcinoma of the lung.
  • She was found to have a large, complex cystic mass in the pelvis, and during the staging evaluation, a large, right pulmonary hilar mass was detected.
  • The patient received 3 cycles of chemotherapy with carboplatin and subsequently underwent a supracervical hysterectomy and bilateral salpingo-oophorectomy.
  • Microscopic examination disclosed a mucinous neoplasm with both mucinous cystadenoma and mucinous papillary adenocarcinoma components.
  • A microscopic focus of cells with "atypical" cytomorphologic features was detected within the mucinous neoplasm.
  • Immunohistochemistry showed that group of cells to be positive for thyroid transcription factor 1 and chromogranin, confirming them to be metastasis from the pulmonary small cell neuroendocrine carcinoma.

  • Genetic Alliance. consumer health - Ovarian small cell carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15722802.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranins; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; EC 1.11.1.- / Peroxidases
  •  go-up   go-down


16. Davì MV, Bodei L, Francia G, Bartolomei M, Oliani C, Scilanga L, Reghellin D, Falconi M, Paganelli G, Lo Cascio V, Ferdeghini M: Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid). J Endocrinol Invest; 2006 Jun;29(6):563-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid).
  • SS receptors are overexpressed in many tumors, mainly of neuroendocrine origin, thus enabling the treatment with SS analogs.
  • The clinical experience of receptor radionuclide therapy with the new analog [90Y-DOTA0-Tyr3 ]-octreotide [90Y-DOTATOC] has been developed over the last decade and is gaining a pivotal role in the therapeutic workout of these tumors.
  • It is well known that some procedures performed in diagnostic and therapeutic management of endocrine tumors, such as agobiopsy and hepatic chemoembolization, can be associated with the occurrence of symptoms related to the release of vasoactive amines and/or hormonal peptides from tumor cell lysis.
  • This is the first report of a severe carcinoid crisis developed after receptor radionuclide therapy with 90Y-DOTATOC administered in a patient affected by liver metastases from bronchial neuroendocrine tumor (atypical carcinoid).
  • Despite protection with H1 receptor antagonists, octreotide and corticosteroids, few days after the therapy the patient complained of persistent flushing of the face and upper trunk, severe labial and periocular oedema, diarrhoea and loss of appetite.
  • The patient received iv infusion of octreotide associated with H1 and H2 receptor antagonists and corticosteroid therapy, which induced symptom remission within few days.
  • The case here reported confirms that radionuclide therapy is highly effective in determining early rupture of metastatic tissue and also suggests that pre-medication should be implemented before the radiopeptide administration associated with a close monitoring of the patient in the following days.
  • [MeSH-minor] Aged. Bone Neoplasms / secondary. Carcinoid Tumor / drug therapy. Carcinoid Tumor / radiotherapy. Humans. Male. Yttrium Radioisotopes / adverse effects

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2002 May;43(5):610-6 [11994522.001]
  • [Cites] Endocr Rev. 2004 Jun;25(3):458-511 [15180952.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jan;12(1):231-42 [12735141.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Jul;31(7):1038-46 [15150675.001]
  • [Cites] Br J Anaesth. 2001 Sep;87(3):447-52 [11517130.001]
  • [Cites] Semin Nucl Med. 2002 Apr;32(2):133-40 [11965608.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):246-54 [8532003.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):207-16 [12552338.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):858-68 [10080850.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Feb;17(3):437-44 [12562458.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):966-73 [15151956.001]
  • [Cites] Am J Clin Oncol. 2000 Aug;23 (4):412-5 [10955874.001]
  • [Cites] Semin Nucl Med. 2002 Apr;32(2):141-7 [11965609.001]
  • [Cites] Eur J Nucl Med. 2001 Apr;28(4):426-34 [11357492.001]
  • (PMID = 16840837.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / 90Y-octreotide, DOTA-Tyr(3)-; 0 / Yttrium Radioisotopes; RWM8CCW8GP / Octreotide
  •  go-up   go-down


17. Okada D, Kawamoto M, Koizumi K, Tanaka S, Fukuda Y: Immunohistochemical study of the expression of drug-resistant proteins in large cell neuroendocrine carcinoma of the lung. Jpn J Thorac Cardiovasc Surg; 2003 Jul;51(7):272-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical study of the expression of drug-resistant proteins in large cell neuroendocrine carcinoma of the lung.
  • OBJECTIVES: In 1999, the World Health Organization categorized pulmonary large cell neuroendocrine carcinoma as a variant of large cell carcinoma.
  • However, an optimal treatment for large cell neuroendocrine carcinoma has not been established yet.
  • Recently, multimodality therapy combining both surgery and adjuvant chemotherapy has been reported as a useful treatment for large cell neuroendocrine carcinoma, but the effect of chemotherapy on it has not yet been fully investigated.
  • Thus, we evaluated immunohistochemical data of the expression of drug-resistant proteins in large cell neuroendocrine carcinoma.
  • METHODS: We identified 10 large cell neuroendocrine carcinomas (1.2%) out of 850 primary lung cancers that had been surgically resected.
  • We examined the immunohistochemical staining of three drug-resistant proteins, namely, P-glycoprotein, metallothionein and glutathione S-transferase-pi to compare large cell neuroendocrine carcinoma with other histological types of lung cancer.
  • RESULTS: The mean tumor cell positivity rates for P-glycoprotein, metallothionein and glutathione S-transferase-pi in large cell neuroendocrine carcinoma were 0%, 2.4 +/- 3.6% and 35.0 +/- 37.5%, respectively.
  • These drug-resistant proteins showed similar expression pattern in both large cell neuroendocrine carcinoma and small cell carcinoma except glutathione S-transferase-pi.
  • CONCLUSION: Immunohistochemical expression of drug-resistant proteins in large cell neuroendocrine carcinoma was lower than that in adenocarcinoma and squamous cell carcinoma, and differences exist in drug-resistance between large cell neuroendocrine carcinoma and small cell carcinoma.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Carcinoma, Neuroendocrine / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Glutathione Transferase / biosynthesis. Isoenzymes / biosynthesis. Lung Neoplasms / pathology. Metallothionein / biosynthesis. P-Glycoprotein / biosynthesis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Glutathione S-Transferase pi. Humans. Immunohistochemistry. Japan. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Surgical Procedures, Operative

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12892456.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / P-Glycoprotein; 9038-94-2 / Metallothionein; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


18. Erhan Y, Dikmen Y, Yucebilgin MS, Zekioglu O, Mgoyi L, Terek MC: Large cell neuroendocrine carcinoma of the uterine corpus metastatic to brain and lung: case report and review of the literature. Eur J Gynaecol Oncol; 2004;25(1):109-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell neuroendocrine carcinoma of the uterine corpus metastatic to brain and lung: case report and review of the literature.
  • Neuroendocrine carcinoma of the uterine corpus is a rare aggressive tumor with a similar unfavorable outcome to that of the cervix.
  • The large cell type is considerably rarer than the small cell neuroendocrine carcinoma of the uterine corpus.
  • We report a case of a 52-year-old woman who presented with a large cell neuroendocrine tumor of the uterine corpus with very aggressive clinical behavior, cerebral and pulmonary metastases six and four months after initial diagnosis and adjuvant radiotherapy, respectively.
  • Despite successful surgical extirpation of the cerebral metastatic lesion she did not respond to chemotherapy and died four months after disease recurrence.
  • [MeSH-major] Brain Neoplasms / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Lung Neoplasms / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15053077.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 31
  •  go-up   go-down


19. De Dosso S, Bajetta E, Procopio G, Cortinovis D, Buzzoni R, Catena L, Platania M, Verzoni E: Pulmonary carcinoid tumours: indolent but not benign. Oncology; 2007;73(3-4):162-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary carcinoid tumours: indolent but not benign.
  • BACKGROUND: The aim of this retrospective study was to analyse the malignant behaviour of low-grade pulmonary neuroendocrine tumours (NETs) treated at our institution.
  • PATIENTS AND METHODS: We reviewed 48 consecutive patients with pulmonary NETs referred to our Medical Oncology Unit between 1998 and 2006, including 33 subjects with typical carcinoids (TCs) and 15 with atypical carcinoids (ACs).
  • Medical treatments used were somatostatin analogues, combined chemotherapy, within study protocols, 5-fluorouracil/dacarbazine/epiadriamycin (FDE), and oxaliplatin plus capecitabine (XELOX).
  • CONCLUSION: Cell type is the strongest determinant of prognosis, and the degree of malignancy increases from TCs to ACs.
  • Moreover, the prognosis of metastatic pulmonary carcinoids is not as good as expected.
  • Our analysis suggests that patients with advanced disease should receive first-line therapy with a somatostatin analogue, with chemotherapy regimens (FDE, XELOX) used in progressing cases.
  • [MeSH-major] Carcinoid Tumor / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18418008.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


20. Langfort R, Rudziński P, Burakowska B: [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment]. Pneumonol Alergol Pol; 2010;78(1):33-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment].
  • Neuroendocrine tumors of the lung represent a broad spectrum of morphologic types that share specific morphologic, immunohistochemical, ultrastructural, and molecular characteristics.
  • The classification of neuroendocrine lung tumors has changed over the last decades and currently four categories are distinguished: typical carcinoid tumor, atypical carcinoid tumor, large cell neuroendocrine carcinoma and small cell carcinoma.
  • Neuroendocrine tumors of the lung comprise approximately 20% of all primary lung cancers.
  • Because of differences in clinical behavior, therapy, and prognosis, a reliable histological diagnosis, as well as clinical and pathological staging system are essential for an appropriate medical proceedings.
  • The most effective treatment of bronchial carcinoids and large cell neuroendocrine carcinoma in an early stage is complete surgical resection, whereas chemotherapy remains the primary treatment for small cell carcinoma.
  • The majority of patients with pulmonary carcinoid have an excellent survival, even if they present with lymph node metastases.
  • Large cell neuroendocrine and small cell carcinoma progress rapidly and are generally widespread at the moment of diagnosis.
  • Increased knowledge about pulmonary neuroendocrine tumors biology and the genetic characteristics, imply that carcinoid tumors appear to have a different etiology and pathogenesis than large cell neuroendocrine and small cell carcinoma.
  • In practice, it could be easiest to conceptualize this group of pulmonary tumors as a spectrum of malignancy ranging from the low grade typical carcinoid to the highly malignant large cell neuroendocrine and small cell carcinoma.
  • Typical carcinoid tumors associated with a fairly benign behavior should be classified as low-grade neuroendocrine tumor/carcinoma (G1) and atypical carcinoid tumors as intermediate-grade tumor/carcinoma (G2).
  • Whereas, large cell neuroendocrine and small cell carcinoma should be grouped together under the designation of high-grade neuroendocrine tumor/carcinoma (G3).
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / therapy. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / therapy
  • [MeSH-minor] Carcinoid Tumor / diagnosis. Carcinoid Tumor / therapy. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / therapy. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / therapy. Humans. Lung / pathology. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20162517.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 67
  •  go-up   go-down


21. Hage R, de la Rivière AB, Seldenrijk CA, van den Bosch JM: Update in pulmonary carcinoid tumors: a review article. Ann Surg Oncol; 2003 Jul;10(6):697-704
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update in pulmonary carcinoid tumors: a review article.
  • Pulmonary carcinoid tumors are neuroendocrine malignant tumors that make up 1% to 2% of all lung tumors.
  • Carcinoids can be placed in a spectrum of neuroendocrine tumors, ranging from low-grade malignant TC to intermediate AC to high-grade large-cell neuroendocrine carcinoma and small-cell lung carcinoma.
  • Familial pulmonary carcinoids are rare.
  • The most common symptoms are hemoptysis, cough, recurrent pulmonary infection, fever, chest discomfort and chest pain, unilateral wheezing, and shortness of breath.
  • The treatment of choice is surgical resection, and prognosis is relatively good in TC, although it is worse in AC.
  • The role of radiotherapy and chemotherapy as part of multimodality treatment or palliation is still debated.
  • [MeSH-major] Carcinoid Tumor / pathology. Lung Neoplasms
  • [MeSH-minor] Biopsy. Bronchoscopy. Chemotherapy, Adjuvant. Combined Modality Therapy. Cough / etiology. Fever / etiology. Hemoptysis / etiology. Humans. Neoplasm Staging. Palliative Care. Prognosis. Radioimmunodetection. Radiotherapy, Adjuvant. Respiratory Sounds / etiology. Somatostatin

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12839856.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 51110-01-1 / Somatostatin
  • [Number-of-references] 65
  •  go-up   go-down


22. Park MS, Kim KD, Chung JH, Shin DH, Chung KY, Kim JH, Lee CY, Kim YS, Kim HJ, Kim SK, Ahn CM, Kim SK, Chang J: Clinical Features of Pulmonary Large Cell Neuroendocrine Carcinoma. Cancer Res Treat; 2003 Jun;35(3):245-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical Features of Pulmonary Large Cell Neuroendocrine Carcinoma.
  • PURPOSE: This study was performed to investigate the clinical features of large cell neuroendocrine carcinomas (LCNEC).
  • RESULTS: The prevalence of LCNEC among primary lung cancers was 0.3%, 37 out of 13, 012 cases over a 10 year period.
  • The tumor was located at the periphery of the lung in 24 cases (65%).
  • The median survival time and 5 year-survival rate were 24 months and 27%, respectively.
  • The possibility of LCNEC needs to be evaluated for the following situations: small cell carcinomas located at the periphery and not responding chemotherapy, small cell carcinomas diagnosed by percutaneous needle aspiration, poorly differentiated non-mall cell carcinomas, with uncertain histologic type, and unclassified neuroendocrine tumor, etc.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 26680943.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Keywords] NOTNLM ; Carcinoma / Large cell / Lung neoplasm / Neuroendocrine tumor
  •  go-up   go-down


23. Beasley MB, Thunnissen FB, Brambilla E, Hasleton P, Steele R, Hammar SP, Colby TV, Sheppard M, Shimosato Y, Koss MN, Falk R, Travis WD: Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol; 2000 Oct;31(10):1255-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary atypical carcinoid: predictors of survival in 106 cases.
  • Pulmonary neuroendocrine tumors (NE) include a spectrum of tumors from typical carcinoid (TC) to atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small cell carcinoma (SCLC).
  • Survival analysis was performed on 106 ACs with clinical follow-up from the AFIP and the Pathology Panel of the International Association for the Study of Lung Cancer (IASLC).
  • Chemotherapy or radiation therapy was given in 12 of 52 and 14 of 52 cases, respectively, but the data were insufficient to evaluate tumor response.
  • We conclude that AC is an aggressive neuroendocrine neoplasm with survival intermediate between TC and LCNEC and SCLC.
  • Surgical resection remains the treatment of choice, and the role of chemotherapy and radiation therapy remains to be proven.
  • [MeSH-major] Carcinoid Tumor / mortality. Lung Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11070119.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


24. Liptak JM, Kamstock DA, Dernell WS, Ehrhart EJ, Rizzo SA, Withrow SJ: Cranial mediastinal carcinomas in nine dogs. Vet Comp Oncol; 2008 Mar;6(1):19-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on histological and immunohistochemical analysis, four dogs were diagnosed with ectopic follicular cell thyroid carcinomas, one dog with ectopic medullary cell thyroid carcinoma, two dogs with neuroendocrine carcinomas and two dogs with anaplastic carcinomas.
  • All dogs survived surgery, but four dogs developed pulmonary thromboembolism and two dogs died of respiratory complications postoperatively.
  • Adjunctive therapies included pre-operative radiation therapy (n=1) and postoperative chemotherapy (n=3).
  • Three dogs had metastasis at the time of diagnosis, but none developed metastasis following surgery.
  • The overall median survival time was 243 days.
  • Local invasion, pleural effusion and metastasis did not have a negative impact on survival time in this small case series.
  • [MeSH-minor] Animals. Carcinoma, Medullary / diagnosis. Carcinoma, Medullary / mortality. Carcinoma, Medullary / surgery. Carcinoma, Medullary / veterinary. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / mortality. Carcinoma, Neuroendocrine / surgery. Carcinoma, Neuroendocrine / veterinary. Dogs. Female. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local / veterinary. Prognosis. Survival Analysis. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / mortality. Thyroid Neoplasms / surgery. Thyroid Neoplasms / veterinary. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178660.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G, Bigiani N, Schirosi L, Casali C, Morandi U, Facciolongo N, Maiorana A, Bavieri M, Fabbri LM, Brambilla E: Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol; 2005 Dec 1;23(34):8774-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.
  • PURPOSE: Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a relatively uncommon, high-grade neuroendocrine tumor sharing several features with small-cell lung carcinoma (SCLC) but currently considered as a variant of non-SCLC and accordingly treated with poor results.
  • Little is known about the optimal therapy of LCNEC and the possible therapeutic molecular targets.
  • PATIENTS AND METHODS: We reviewed 83 patients with pure pulmonary LCNEC to investigate their clinicopathologic features, therapeutic strategy, and immunohistochemical expression and the mutational status of the receptor tyrosine kinases (RTKs) KIT, PDGFRalpha, PDGFRbeta, and Met.
  • At univariate and multivariate analysis, SCLC-based chemotherapy (platinum-etoposide) was the most important variable correlating with survival, both in the adjuvant and metastatic settings (P < .0001).
  • CONCLUSION: Pulmonary LCNEC represents an aggressive tumor requiring multimodal treatment even for resectable stage I disease, and LCNEC seems to respond to adjuvant platinum-etoposide-based chemotherapy.
  • Patients who received this therapy had the best survival rate.
  • Despite our failure in finding mutational events in the tested RTKs, the strong expression of KIT, PDGFRalpha, PDGFRbeta, and Met in tumor cells suggests an important role of these RTKs in LCNEC, and these RTKs seem to be attractive therapeutic targets.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / drug therapy. Carcinoma, Neuroendocrine / drug therapy. Lung Neoplasms / drug therapy. Receptor Protein-Tyrosine Kinases / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / enzymology. Carcinoma, Small Cell / mortality. Cisplatin / administration & dosage. DNA Mutational Analysis. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Paclitaxel / administration & dosage. Polymerase Chain Reaction. Proto-Oncogene Proteins c-kit / biosynthesis. Proto-Oncogene Proteins c-kit / genetics. Proto-Oncogene Proteins c-met / biosynthesis. Proto-Oncogene Proteins c-met / genetics. Receptor, Platelet-Derived Growth Factor alpha / biosynthesis. Receptor, Platelet-Derived Growth Factor alpha / genetics. Receptor, Platelet-Derived Growth Factor beta / biosynthesis. Receptor, Platelet-Derived Growth Factor beta / genetics. Survival Analysis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314638.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Proto-Oncogene Proteins c-met; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Hollaus PH, Wurnig PN, Pridun NS: [Bronchoplastic procedures for the resection of malignant bronchial neoplasms]. Chirurg; 2002 Nov;73(11):1115-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Bronchoplastic procedures have become established in the treatment of bronchial malignancies.
  • PATIENTS AND METHODS: Bronchial reconstruction techniques (wedge resection, end-to-end-anastomosis, y-sleeve), comorbidity (cardiovascular, respiratory, pulmonary, neoadjuvant chemotherapy, alcoholism), postoperative complications (septic/aseptic, light/severe), histology, tnm-stage and postoperative follow up (days) were recorded prospectively.
  • In 11 patients (10.2%), an additional angioplasty of the pulmonary artery was performed.
  • CONCLUSION: Bronchoplastic procedures are a safe method for the treatment of bronchial malignancies, even in cases with high comorbidity, and should be performed whenever possible.
  • [MeSH-major] Adenocarcinoma / surgery. Bronchi / surgery. Bronchial Neoplasms / surgery. Carcinoma, Neuroendocrine / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Anastomosis, Surgical. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Pneumonectomy. Postoperative Complications / etiology. Postoperative Complications / mortality. Risk Factors. Survival Rate

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12430063.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. Wang X, MacLennan GT, Lopez-Beltran A, Cheng L: Small cell carcinoma of the urinary bladder--histogenesis, genetics, diagnosis, biomarkers, treatment, and prognosis. Appl Immunohistochem Mol Morphol; 2007 Mar;15(1):8-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the urinary bladder--histogenesis, genetics, diagnosis, biomarkers, treatment, and prognosis.
  • Most patients present with advanced disease at the time of diagnosis.
  • Histologically, small cell carcinoma of the urinary bladder is indistinguishable from its pulmonary counterpart.
  • Coexistence with other types of carcinoma is common.
  • Histogenesis is uncertain; there are several competing theories, including origin from stem cells, from urothelial cells, and from neuroendocrine cells in normal or metaplastic urothelium.
  • Immunohistochemical staining can be extremely helpful in establishing the diagnosis, and in investigating the use of potential therapeutic strategies.
  • Currently, combinations of surgical resection, chemotherapy, and radiation therapy represent the main treatment options.
  • Improvement in survival may depend upon the identification of new molecular markers to facilitate earlier diagnosis and the development of novel targeted therapies.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536302.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 63
  •  go-up   go-down


28. Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Baba M, Fujisawa T, Ohwada H: Adjuvant chemotherapy for large cell carcinoma with neuroendocrine features. Cancer; 2001 Sep 1;92(5):1108-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy for large cell carcinoma with neuroendocrine features.
  • BACKGROUND: In 1999, the World Health Organization categorized large cell neuroendocrine carcinoma, large cell carcinoma with neuroendocrine differentiation, and large cell carcinoma with neuroendocrine morphology as a variant of large cell carcinoma.
  • Patients with large cell carcinoma with neuroendocrine features have poor prognoses, comparable to those for small cell lung carcinoma.
  • Small cell lung carcinoma is sensitive to chemotherapy; however, it is still unclear whether large cell carcinoma with neuroendocrine features is responsive to adjuvant chemotherapy.
  • METHODS: The authors analyzed 73 patients with large cell carcinoma with neuroendocrine features who underwent resection of the tumor and studied the effect of adjuvant chemotherapy for large cell carcinoma with neuroendocrine features.
  • RESULTS: In patients with Stage I disease, the overall survival for patients with adjuvant chemotherapy based on cisplatin, carboplatin, or cyclophosphamide, which were used as standard chemotherapy for small cell lung carcinoma, were significantly higher than the overall survival for patients without adjuvant chemotherapy.
  • In patients with Stage II, III, and IV disease, there was no significant difference between patients with adjuvant chemotherapy and without adjuvant chemotherapy.
  • CONCLUSIONS: Adjuvant chemotherapy based on cisplatin, carboplatin, or cyclophosphamide prolongs survival of patients with large cell carcinoma with neuroendocrine features in early stage.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carcinoma, Neuroendocrine. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pneumonectomy. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11571722.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement